EXECUTION DRAFT: Feb 08-08

RESEARCH AGREEMENT

This agreement (the "Agreement") is made between **Primera Bioscience Research Inc.** ("PRIMERA") having a principal place of business at Suite 2500, 120 Adelaide Street West, Toronto, Ontario M5H 1T1, and **The Hospital for Sick Children** having a principal place of business at 555 University Avenue, Toronto, Ontario M5G 1X8 ("HSC) on February 8, 2008 ("Effective Date").

This Agreement is intended to set out the general terms and conditions by which PRIMERA shall provide, and HSC shall receive, funding for the project described in the attached Exhibit A (the "Project").

HSC and PRIMERA agree to work together in the funding and further development of the Project under the following terms and conditions:

1. Funding and Development of the Project

1.01 PRIMERA agrees to provide funding through an unrestricted grant in the total amount of $300,000.00, inclusive of 25% overhead, for the Project as described in Exhibit A in collaboration and consultation with HSC. Exhibit A may be amended from time to time by mutual written agreement of HSC and PRIMERA.

1.02 HSC agrees to perform the development of the Project in accordance with technical and professional standards, and in accordance with all laws, rules and regulations applicable to the conduct of the development of the Project, but does not promise success in achieving any desired result. HSC gives no warranty of fitness for a particular purpose, or any other warranty, express or implied, on the results of the development of the Project.

1.03 Unless otherwise indicated, all dollar amounts in this Agreement are expressed in Canadian funds. PRIMERA shall make payments by cheque to **The Hospital for Sick Children** in accordance with the following payment schedule:

Upon execution of this Agreement	$100,000
August 1, 2008	$100,000
1 year anniversary of this Agreement	$100,000

Cheques will be sent to: The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8, **Attn: Susan Malench, Director, Research Awards & Finance, Research Institute, Account No.: 3332145051**

2. Progress Reporting

HSC shall provide PRIMERA with a summary every 6 months concerning its progress in conducting the development of the Project. PRIMERA and HSC agree to meet in person or by telephone at mutually acceptable times and places to discuss progress, challenges encountered and any ideas, concepts or inventions conceived in the course of the development of the Project.

3. Confidentiality

Except to the extent required by law, or by any regulatory authority having jurisdiction, none of the parties shall make public disclosure of Confidential Information (as defined below), the terms of this Agreement or the transactions provided for in such agreement without the prior written consent of the other parties; the parties shall co-operate in good faith as to the content and timing in making any such required or agreed public disclosure. HSC may disclose the existence of this Agreement, identify the parties to this Agreement, and disclose the amount of funding actually received from PRIMERA pursuant to this Agreement.

"Confidential Information" shall mean any and all written confidential and proprietary information of the PRIMERA and HSC which may be exchanged between the parties at any time before and during the term of this Agreement including, without limitation, business and marketing information, technology, ideas, data, reports, compounds, molecules, cell lines, know-how, techniques, methods, processes, uses, composites, skills, and configurations of any kind.

The obligations of confidentiality shall not apply to the extent that the information (i) was already known to the relevant party without restriction at the time the information was disclosed to such party; (ii) was generally available to the public or otherwise as part of the public domain at the time of its disclosure to the relevant party; (iii) became generally available to the public or otherwise part of the public domain after its disclosure to the relevant party through no act or omission of such party; or (iv) was disclosed to the relevant party without restriction by a third party who, to the best of such party's knowledge and belief, had no obligation not to disclose such information.

4. Ownership of Intellectual Property

HSC shall own the intellectual property invented or created by its employees, appointees or trainees before, during and after the development of the Project as shown in Exhibit B, (the "Intellectual Property").

5. Sharing of Proceeds of Commercialization

5.01 Any proceeds received by HSC from commercialization agreements pertaining to the Intellectual Property hereunder (the "Proceeds") shall first be applied to offset costs for (i) filing, prosecuting, securing and maintaining the intellectual property rights for the Intellectual Property; and, (ii) expenses for third party services provided solely for the purpose of commercializing the Project Subject to section 4, after HSC has recovered such costs, ten (10%) percent of any remaining proceeds shall be remitted to PRIMERA.

ii) HSC shall make such remittance to PRIMERA within thirty (30) days after the end of each calendar quarter within which HSC receives such proceeds. Income derived by HSC from *bona fide* professional services performed pursuant to such commercialization agreements and/or third party funding of the further development of the Project, shall not be considered proceeds subject to the terms of this agreement.

iii) If an arrangement for commercialization of the Intellectual Property is made which results in consideration other than cash flowing to HSC, the parties agree to share such non-cash consideration in the same proportion as provided in section 4. HSC shall have the right at any time to liquidate the non-cash assets without the approval of PRIMERA.

6. Financial Reporting, Audit & Inspection Rights

6.01 Research expenditures and any payments to PRIMERA shall be accompanied by a statement showing in reasonable detail the computation and derivation of the expenditures, Proceeds and such payments.

6.02 HSC shall maintain accurate and complete records relating to the calculation of the Proceeds and these records shall be audited by HSC's auditor applying generally accepted accounting principles at the end of HSC's fiscal year:

(a) a copy of the audited calculation shall be delivered to PRIMERA within 120 days following the end of HSC's fiscal year to which it relates;

(b) any necessary adjustment in payments of PRIMERA's share of the

Proceeds revealed by the audit shall be made by HSC to PRIMERA or by PRIMERA to the HSC, as the case may be, within 150 days of HSC's fiscal year end; and

(c) PRIMERA shall have 60 days after receipt of the audited calculation to question its accuracy in writing, and failing such objection, the calculation shall be deemed correct.

6.03 PRIMERA, or its duly appointed agent, shall have the right once each calendar year, at a mutually convenient time to be agreed upon by the parties, to inspect the books and records relating to the calculation of the Proceeds.

7. Liability

HSC assumes its own liability for any loss, claim or damage which may arise directly in the course of its own activities in carrying out the development of the Project, provided that such loss, claim or damage does not arise from negligence or wrongdoing on the part of PRIMERA. HSC shall not be liable for any direct, consequential or any other damage suffered by PRIMERA or others resulting from the use of the results of the development of the Project or the Intellectual Property.

8. Assignment

Neither party may assign this Agreement or their rights and obligations hereunder to any other party without the consent of the other party, provided that HSC may assign this Agreement and its rights and obligations hereunder to any affiliate, subsidiary or other entity which it may establish for the provision of any and all services under this agreement.

9. Independent Contractors

The relationship of the Parties hereto is that of independent contractors and nothing in this Agreement shall be construed as establishing an agency, partnership or employment relationship among the Parties. No party shall have the authority to make any statements, representations or commitments of any kind, or take any action which shall be binding on the other party, except as may be explicitly provided for herein or authorized by the other party in writing.

10. Effective Date & Termination

10.01 This Agreement shall come into effect on the Effective Date and unless earlier terminated, shall extend until the expiry of the last of the patents pertaining to the Intellectual Property.

10.02 In the event of a material breach of this Agreement by either party, the party not in breach shall have the right to terminate this Agreement by providing written notice to the party in breach, and such termination shall be effective upon the ninetieth (90) day after mailing such notice, unless the party in breach, has cured such breach prior to the ninetieth (90) day.

11. Additional Representations and Warranties

Each of the Parties hereto represents and warrants to the other that:

(a) it is duly formed and validly subsists under all applicable laws and has the corporate power and authority to enter into the transactions contemplated hereby;

(b) it has taken all necessary action to authorize such execution, delivery and performance;

(c) the Agreement constitutes legal, valid and binding obligations enforceable against it except as enforceability may be limited to applicable laws relating to enforcement of creditor's rights generally;

(d) the execution, delivery and performance by it of this Agreement will, at all times, comply with all applicable laws and regulations including those of applicable securities regulatory authorities and self-regulatory organizations; and

(e) the execution, delivery and performance by it of this Agreement does not conflict with any contracts or other obligations to which it may be bound and does not conflict with and does not and will not result in a breach of its articles, by-laws or resolutions.

12. Notice

(a) Any notice, offer, payment, certificate or other communication required or desired to be given in connection with this Agreement shall be given in writing and sent by facsimile or delivered personally or may be sent by prepaid registered post addressed as follows:

if to PRIMERA:

MB Bioscience Research Inc.
Suite 2500
120 Adelaide Street West
Toronto, Ontario
M5H 1T1
Attention: Dennis H. Peterson
Facsimile: 416-352-5693

if to HSC:

The Hospital for Sick Children
555 University Avenue
Toronto, Ontario
M5G 1X8
Attention: Arlene J. Yee
Facsimile: 416-813-5968

(b) Any notice so delivered shall be deemed to have been received at the time of delivery or facsimile, and any notice so mailed shall be deemed to be effectively given and received on the 4th business day following the date of mailing;

(c) Any one of the parties may change its address for the purpose of this paragraph by giving notice of such change of address to the other in the manner provided herein.

13. General

13.01 All references to currency herein shall be deemed to refer to Canadian dollars.

13.02 This Agreement shall be construed and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein.

13.03 Any disputes under this Agreement shall be submitted to binding arbitration consisting of a panel of three arbitrators, one arbitrator appointed by each of the parties with a third arbitrator appointed by the parties' two

designated arbitrators, with all costs of such arbitrator to be borne by the unsuccessful party(ies).

13.04 None of the parties hereto shall be responsible to the other of them for non-performance or delay in performance occasioned by any causes beyond its control, including without limitation, acts or omissions of the other of them, acts of civil or military authority, strikes, walkouts, embargoes, acts of God, delay of suppliers, or inability to obtain, or shortages of, materials or supplies, other than for financial reasons and other than equipment failure caused by the failure of HSC to maintain properly or repair within a reasonable time such equipment.

13.05 This Agreement may not be amended or modified in any respect except by written instrument signed by each of the parties hereto.

13.06 All representations and warranties made by the parties in this Agreement shall continue after the Effective Date, regardless of any investigation by a party prior to the Effective Date.

13.07 All fees and expenses incurred by each party in connection with this Agreement shall be borne by such party, including without limitation all fees of counsel.

13.08 If any provision of this Agreement is found to be unenforceable, the remaining provisions hereof shall nevertheless remain in full force and effect.

13.9 Time is of the essence of this Agreement and will be calculated in accordance with the provisions of the Interpretation Act (Ontario).

13.10 The parties hereto hereby covenant and agree at any time subsequent to the Effective Date and from time to time to execute and deliver such further and other assignments, transfers, conveyances and documents as counsel for the parties may reasonably deem necessary to give effect to the transaction herein.

13.11 This Agreement, including the schedules hereto, constitutes the entire Agreement between the parties. There are no and shall not be any verbal statements, representations, warranties, undertakings or agreements between the parties.

13.12 This Agreement shall enure to the benefit of and be binding upon the parties hereto and their respective successors and assigns.

13.13 This Agreement may be executed in several counterparts, each of which when so executed shall be deemed to be an original, and such counterparts

together constitute one and the same instrument, and notwithstanding the date of execution shall be deemed to bear the date as of the date written in the beginning of this Agreement.

IN WITNESS WHEREOF the parties have executed this Agreement and agree to be bound hereby as of the date first written above.

PRIMERA BIOSCIENCE RESEARCH INC.

By: _____
(Signature)

Name: Dennis H. Peterson

Title: Corporate Secretary

THE HOSPITAL FOR SICK CHILDREN

By: _____
(Signature)

Name: Stuart D. Howe

Title: Director, Corporate Ventures

Exhibit A: Schedules of the Project to be Funded

Proposal

Peter Dirks, MD, PhD
Hospital for Sick Children, University of Toronto

Targeting Brain Tumor Stem Cells in vivo with Novel Chemotherapeutic Agents

Introduction

Recent data from several laboratories including our own have demonstrated that cancer is a stem cell disease: cancer growth depends on a rare population of cells within the cancer tissues which have stem cell properties[1]. Most of the cells that comprise the bulk of the cancer do not have the ability to sustain cancer growth. The "cancer stem cells" possess similar properties to normal stem cells, the ability to self renew, to generate more stem cells, and the ability to differentiate, to create large populations of mature cells that comprise the bulk of the tissue. Cancer has also been described as a disease of unlimited self renewal, or a defect in cells to differentiate. Applying the principles of stem cell biology is providing new insight into brain tumors, leukemia, breast cancer, colon cancer, prostate cancer, and pancreatic cancer, and many other cancers may be also proven to be driven by rare populations of stem cells that reside within.

In 2004, our laboratory identified the cancer stem cells in human brain tumors from children and adults. Currently, the therapy for these tumors is limited and the mortality rates are among the highest for any human cancer. The discovery of these cancer stem cells in human brain tumors suggests that current treatments spare these rare cancer cells, and that to effect brain tumor cure, these cells must be targeted.

Recently, our laboratory, together with Mike Tyers laboratory (formerly Mt Sinai Hospital, now University of Edinburgh) has engaged in drug discovery studies for cancer stem cells, by performing a chemical biology screen on normal brain stem cells (neural stem cells) from mouse[2]. This screen, the first drug screen published on normal neural stem cells, identified a number of drugs that slowed the growth of these cells in a culture system. These drugs also subsequently showed the ability to slow the growth of human neural stem cells, and as well, human and mouse brain tumors in culture. The library of compounds that we used in our screen contained many drugs in clinical use, but they were not previously identified as anti-cancer drugs. As they have been used on human patients for other brain diseases (such as depression and Parkinson's), they could theoretically more rapidly deployed for clinical use if they show effect on further laboratory studies in animal models. As well, as many of the drugs that showed effect are used in human brain diseases, we know that they penetrate into and have pharmacologic activity in the central nervous system, which overcomes an important barrier to the application of novel compounds, that is, the difficulty in getting drugs administered systemically (orally or intravenously) into the brain so that they may exert their activity. We have submitted for patent protection of 160 drugs for their use in human brain tumors, but so far have only characterized 41 drugs, and only 10 in great detail.

Moving Forward

In going forward with this work, and before application to human patients, we need to determine if they are effective in treating brain tumors in experimental animal models.

We have recently established, in our laboratory, an in vivo orthotopic cancer stem cell model to study human brain tumor stem cells (published, Nature 2004), and we have also identified cancer stem cells in an important genetically engineered mouse model, where mice deficient for

the gene Patched1, develop medulloblastomas which are identical to those that occur in young children (unpublished).

Aim

In this proposal, we will test if drugs (small chemical molecules) that we have shown that show potent anti-normal neural stem cell and brain tumor stem cell effect (in mouse and human cells) in culture are effective treatments for brain tumors in two experimental models of brain cancer, one human, and one mouse. The most important experiments involve human cells, but the mouse model which spontaneously develops brain tumors has advantages as these tumors can be very efficiently generated. The human models are mainly for adult tumors, and the mouse models are exclusively for childhood tumors.

Methods

1. **Human Brain Tumor Stem Cell Xenografts in Immunodeficient Mice**

Our laboratory has established 15 brain tumor stem cell lines from primary human tumors. Seven of these lines are now extensively characterized These lines retain stem cell properties in vitro and retain the ability to efficiently initiate the growth of brain tumors after injection into immunodeficient mice, so they are ideal reagents for drug testing in a preclinical model of human brain tumors.

For this study, we will initially test 5 drugs on 5 different human glioblastoma brain tumor stem cell lines. Glioblastomas are the most common malignant human brain tumors of adults and they have a very poor survival (10% 2 year survival). For each brain tumor stem line, we will perform two types of studies. We will first test the effect of drug administered immediately after human brain tumor cells are injected, to see if the drug prevents tumor engraftment in these animals. This situation will mimic early treatment of brain tumors. However, a more clinically realistic situation involves treatment of established tumors. We will therefore allow tumors to grow for 4-8 weeks, and then will commence treatment with drug.

Because the only realistic model of human brain tumors involves growing the tumor cells in the brains of mice, these studies remain technically challenging. I do not believe that growing brain tumor cells subcutaneously (which allows palpation and measurement of tumors) is realistic, because we will still need to verify the effects on tumor cells growing in the brain. Drugs that show effect on tumors implanted subcutaneously may have no effect when tumors are implanted into the brain, due to the blood brain barrier that excludes drugs from gaining entry into the brain tissue. As we have brain tumor stem cell lines that reliable engraft the brains of immunodeficient mice, we have a reliable system to carry out these drug studies.

These studies will determine if any of our drug candidates treat the most malignant brain tumor that occurs in adults.

2. **Treatment of Mouse Medulloblastomas in the Patched-deficient Mice**

When Patched deficient mice are crossed with p53 deficient mice, we can get medulloblastoma tumors arising in 100% of these mice within 8 weeks of live birth. We can therefore treat mice shortly after birth to determine if drug prevents formation of medulloblastomas in this model, and we can wait for tumors to grow to determine if drug shrinks established tumors (we will focus on our 5 best drugs initially). We can also make tumor stem cell lines from these mouse tumors and inject them into immunodeficient mice, so that we can also use a model system that is close to the human model system described above.

These studies will determine if any of our drugs show efficacy on a mouse brain tumor that closely resembles the commonest type of malignant brain tumor that occurs in children.

Timeline of Experiments

The main purpose of this proposal is to perform the necessary experiments on brain tumor animal models using our best previously identified drugs in order to bring them to clinical trial for human brain tumor patients. Our aim is to get as much good quality in vivo data as fast as possible. These studies, therefore, will be the stepping stone to human clinical trial.

We will focus initially on our 5 best agents that were defined in our previously published stem cell culture studies. If these agents are not effective, we will move to our next best 5 agents. It may be difficult to predict which will be the most effective agents in vivo based on potency in vitro. By the end of the first year we will have tested the first 5 agents and can move to the next 5 over the next 12 months. We will likely test more than 10 compounds as our efficiency will improve over the course of the 2 year study period. For any compound that shows effectiveness in the animal models, our goal will be to move quickly to establishing a clinical trial for that agent. To perform a clinical trial we will have to raise additional funds, through Grants from Cancer Agencies, private companies, or through the establishment of our own start up company.

We will also use one additional strategy to obtain further value from this project. We will perform in vitro dose response analysis (secondary screens) for the next 50 compounds out of the 160 original hits (43 compounds out of 160 hits were characterized in detail in our initial study). This experiment will determine the next candidate agents (expect 10-20) for the next phase of testing in vivo. We will begin to perform these experiments early in the first year of this project, so that any particularly interesting compound will be fast tracked for the in vivo study. For this experiment the 50 compounds will be ordered directly from the source manufacturer at an expected cost of $10,000.

We anticipate the first set of "go/no go" decisions to work torward to clinical trial for our first 5 drugs after 12-18 months.

References

1. Singh, S.K., *et al.* Identification of human brain tumour initiating cells. *Nature* **432**, 396-401 (2004).
2. Diamandis, P., *et al.* Chemical genetics reveals a complex functional ground state of neural stem cells. *Nature chemical biology* **3**, 268-273 (2007).

BUDGET

Estimated costs:

Equipment (see quote) Tissue Processor	$57,950
Personnel Salaries and benefits 1.0 FTE Research technical position (Level II, step 3, Master's degree+experience) For tumor transplant and animal treatments 0.5 FTE Research technical position (Level II, step 3, Master's degree+experience) For analysis of brains in controls and treated animals	$130,000
Mouse costs -NOD/SCID for human xenografts -Ptc1+/- mice, breeding for medulloblastoma model	$25,000
Tissue Culture Costs	$15,000
50 Compounds for secondary screens	$11,500
25% Overhead on Direct Costs **(not including equipment purchase)**	**$60,513**
GRAND TOTAL	**$ 299,963**

Narrative

We will need 2 years to perform these studies.

The automated tissue processor will be required for us to do higher throughput analysis of the histology of brains of animals that have brain tumors, both treated and untreated. This piece of equipment will tremendously save personnel working hours.

We need at least one fulltime technologist and one 0.5 FTE technologist to support the project, ideally for 2 years. The fulltime technologist will culture the human brain tumor stem cell lines, inject animals with brain tumor cells, and treat them with selected experimental drug agents. The halftime technologist will perform processing of samples for histological analysis to determine the response of the tumor to experimental drug treatment.

We will need to continually generate human xenografts in NOD-SCID mice for these studies, and we will also need to keep Ptc1/p53-deficient mice breeding so that their offspring develop medulloblastomas. It is estimated that mouse costs will at least be $25,000.

As human stem cell lines are cultured in serum free media, which is expensive, we estimate that a minimum amount of media with specific growth factors to sustain growth of these cultures will be $20,000.

Exhibit B: Patent Applications

US Patent Application Serial No. 60/851,615
Filed: October 13, 2006
Title: Compositions and methods for treating neurological disorders or damage

Exhibit C.

Quotation

Automated Vacuum Tissue Processor

DR. Ian Clarke
HOSPITAL FOR SICK CHILDREN
RESEARCH DEPARTMENT
555 UNIVERSITY AVENUE
TORONTO ON, M5G 1X8
Office number: 416-813-8096
Fax number: 416-813-8456
EMail: iclarke@sickkids.ca

Leica MICROSYSTEMS

Standard Quote TM0430
Customer No. 0001212442

Date May / 1 / 2007
Sales Person Tim McGill
Customer Care Agent Christine MacCallum
Contact No. 800-205-3422 Ext. 2008

Leica ASP300 S - Automated Vacuum Tissue Processor

- 100-120 V/50-60 Hz



Item	Description	Qty	List Price CAD	Total CAD
100	Leica ASP300 S-- Automated Vacuum Tissue Processor Leica ASP300 S - Vacuum Tissue Processor Freestanding unit - 100-120 V/50-60 Hz The Leica ASP300 S is a freestanding, fully-enclosed vacuum tissue processor for programmable processing of histological tissue specimens in the fields of pathology and clinical histology. The instrument features 3 pressure/vacuum options (pressure & vacuum, pressure only, vacuum only) as well as further option of processing under ambient conditions. Processing temperatures are programmable for each individual step (10 reagent stations and three paraffin wax baths). The instrument provides three cleaning stations plus an optional connection for an external cleaning station. The 4.5-liter processing retort is made of electropolished stainless steel for easy cleaning with a contact-free optical sensor to check the fluid level. Retort capacity for up to 300 standard cassettes when using metal baskets or 252 standard cassettes when using the microwave resistant basket set for ASP300 S (optional accessory). A selection of four further cleaning programs, which can be customized by the operator, are available. An easy-to-use remote reagent handling system can drain and refill reagent bottles from bulk containers via the retort and a hose plugged into the processor module. The 3-step retort draining system is tailored to minimize reagent carry-over. A multi-language user interface combined with a new graphical program display allows even junior operators to quickly become familiar with the system. Ease of use is supported	1	57,950.00	57,950.00

DR. Ian Clarke
HOSPITAL FOR SICK CHILDREN
RESEARCH DEPARTMENT
555 UNIVERSITY AVENUE
TORONTO ON, M5G 1X8
Office number: 416-813-8096
Fax number: 416-813-8456
EMail: iclarke@sickkids.ca

Leica MICROSYSTEMS

Standard Quote	TM0430	**Date**	May / 1 / 2007
Customer No.	0001212442	**Sales Person**	Tim McGill
		Customer Care Agent	Christine MacCallum
		Contact No.	800-205-3422 Ext. 2008

Item	Description	Qty	List Price CAD	Total CAD

further by direct-access on-line help covering each individual processing step.
In addition laboratory-specific custom help (or SOP for GLP) can be installed by the user.
The quick-start feature (from 'Favorites' screen) allows the user to access the instrument without loosing valuable time.
Additional features and functionalities of this state-of-the-art processor include:

- User access control and monitoring viamultiple-step password protection
- Large, high-quality color LCD touchscreen,solvent-resistant
- Intelligent user interface (protectingagainst programming and operation errors)
- Intelligent Reagent Management System - RMS(can be switched ON/OFF)
- Export function of RMS data to standardspreadsheet programs (Excel or others)
- Labels for reagent bottles with 'reagentgroup' color coding for different reagent types and concentrations
- Microwave-resistant plastic baskets forcassettes
- Powerful stirrer unit for efficientinfiltration and even reagent temperatures throughout the retort
- "Fast" infiltration protocols for urgentbiopsies
- Funnel for splash-free filling of thereagent bottles
- Efficient paraffin wax cleaning system
- Programmable delay of "finish time" andme"
- Skip-step / Add-step function (programs canbe edited while in progress)
- Lock mode prevents unauthorized access to anyfunctions or operations of the instrument
- 2-Phase fume control system: condenser toremove solvents from air inside the ins- trument plus activated carbon filter and optional exhaust air hose
- Remote alarm connection
- Auto-protection against overheating andoverpressure
- Sophisticated specimen features afterpower failure - automatic processing recovery
- Full protection against cross-contaminationof incompatible reagents
- Intelligent specimen protection feature
- Quality control feature (system monitoring)including performance check (pump age, carbon filter age, rotary valve performance) and system performance on station level (reagent age monitoring, warning thresholds)
- Serial port
- External printer connection
- 3.5 inch floppy disk drive

DR. Ian Clarke
HOSPITAL FOR SICK CHILDREN
RESEARCH DEPARTMENT
555 UNIVERSITY AVENUE
TORONTO ON, M5G 1X8
Office number: 416-813-8096
Fax number: 416-813-8456
EMail: iclarke@sickkids.ca

Leica MICROSYSTEMS

Standard Quote	TM0430	**Date**	May / 1 / 2007
Customer No.	0001212442	**Sales Person**	Tim McGill
		Customer Care Agent	Christine MacCallum
		Contact No.	800-205-3422 Ext. 2008

Item	Description	Qty	List Price CAD	Total CAD

- Selectable buzzer volume (alarms)
- Design, materials and workmanship incompliance with CE, UL, c-UL, VDE standards.

Technical Data:

Dimensions: (W x H x D): 595 mm x 1325 mm x 680 mm
Dimensions: (W x H x D): 23.43 x 52.17 x 26.77 inches
Dry weight: approx. 140 kg / 308.37 lbs
Nominal supply voltage: 100-120 V/50-60 Hz
Required ambient conditions to ensure functioning according to specifications:
Relative humidity: 80 %, non-condensing
Room temperature: 15 °C to 40 °C
Retort volume: 4.5 l
Admissions: Design, materials and workmanship with CE, UL, c-UL, VDE-standards

Standard delivery includes:

1 Leica ASP300 S - Basic instrument (0476 43515)
1 Accessory kit (0476 43727) consisting of:

- 1 Basket hook (0476 34713)
- 3 specimen baskets, assy, including lid,
- dividers, springs and handle (0476 34193)
- 1 Stirrer bar (0476 43630)
- 1 Reagent bottle with cap, plastic,
- (0476 34274)
- 2 Set Labels for reagent bottles (0200 43464)
- 1 Funnel (0476 43631)
- 2 Activated carbon filters, assy. (0476 34150)
- 1 Remote fill/drain hose, assy.
- w/connnecting device (0476 34716)
- 1 Paraffin drain hose (0476 34721)
- 1 Paraffin wax scraper, plastic (0476 35923)
- 1 Lubricant for valves and O-rings,
- Molykote 111, 100 g (0336 35460)
- 1 Jumper cable - mains (0411 34604)
- 1 Maintenance kit:
- (2 spare lids, 9 O-rings) (0476 35921)
- 1 Splash protection (0476 34770)
- 1 Allen key, size 3.0 (0222 04138)
- 1 Jack connector (remote alarm) (6844 01005)13 Reagent bottles with caps, plastic (included in the instrument) (0476 34274) 1 Condensate bottle with cap, plastic (included in the instrument) (0476 34278) 1 Set

DR. Ian Clarke
HOSPITAL FOR SICK CHILDREN
RESEARCH DEPARTMENT
555 UNIVERSITY AVENUE
TORONTO ON, M5G 1X8
Office number: 416-813-8096
Fax number: 416-813-8456
EMail: iclarke@sickkids.ca

Leica
MICROSYSTEMS

Standard Quote TM0430
Customer No. 0001212442

Date May / 1 / 2007
Sales Person Tim McGill
Customer Care Agent Christine MacCallum
Contact No. 800-205-3422 Ext. 2008

Item	Description	Qty	List Price CAD	Total CAD
	of power cords: - 1 Power cord "USA-C-J" (0411 13559)1 Service kit for pump (included in the instrument) (0476 35922) 1 Drip tray (included in the instrument) (0476 37350) 1 3,5 Diskette, empty (taped to the back of console cover) 1 Instruction manual Leica ASP200/300 S multilingual **No : 14047643515**			
200	Volume replacement device, assy. **No : 14048037127**	1	175.00	175.00
	Sub Total :			58,125.00
	Total :			**58,125.00**

Payment terms : 30 days net

Shipping terms : FOB - Warehouse/POE Prepaid & Added : Prepaid on orders over $2500.00

Validity : 05/01/07 **to** 05/31/07

DELIVERY: 4-6 weeks after receipt of written Purchase Order.
WARRANTY: One (1) Year on parts and labour
PRICES: Taxes not included

Leica 's Standard terms and conditions apply. A copy is available on request.
Thank you for your interest in Leica products.